Celldex Therapeutics Inc (NAS:CLDX)

$ 36.92 0.6 (1.65%) Market Cap: 2.43 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 2.90 GF Score: 62/100

Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 Transcript
Feb 25, 2024
Celldex Therapeutics Inc Conference Call & Webcast Transcript
Nov 06, 2023
Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Celldex Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Mar 30, 2023
Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria Transcript
Feb 26, 2023
Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call Transcript
Dec 06, 2022
Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 Transcript
Jun 30, 2022
Q4 2021 Celldex Therapeutics Inc Earnings Call Transcript
Feb 28, 2022

$29.9 (-0.83%)

Earnings
Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 16, 2022
Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call Transcript
Jul 12, 2021
Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update Transcript
Mar 29, 2021
Q2 2020 Celldex Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

$11.71 (+1.39%)

Earnings
Celldex Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 18, 2020
Q2 2019 Celldex Therapeutics Inc Earnings Call Transcript
Aug 07, 2019

$2.16 (+3.85%)

Earnings
Q4 2018 Celldex Therapeutics Inc Earnings Call Transcript
Mar 07, 2019

$4.6 (-1.71%)

Earnings

Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 Transcript

Jun 30, 2022 / 10:30PM GMT

Release Date Price: $26.96 (-3.13%)

Transcript

Operator

Good evening, and thank you for standing by. Welcome to the Celldex Therapeutics Corporation Update Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your host today, Sarah Cavanaugh. Please go ahead.

Sarah Cavanaugh

Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration

Good evening, and thank you for joining us tonight to discuss interim results from our Phase Ib multiple-ascending dose study of barzolvolimab in patients with chronic spontaneous urticaria, which were released tonight at the EAACI 2022 Annual Meeting.

On our call this evening, I have Anthony Marucci, Co-Founder, President and CEO; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; Dr. Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs and Medical Lead of the program; and Dr. Diego Alvarado, Executive Director of Research

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.